Alberta Childhood Cancer Survivorship Research Program.
childhood cancer
epidemiology
pediatric cancer
survivorship
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
06
05
2023
revised:
07
06
2023
accepted:
15
06
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Adverse outcomes after childhood cancer have been assessed in a range of settings, but most existing studies are historical and ascertain outcomes only after 5-year survival. Here, we describe the Alberta Childhood Cancer Survivorship Research Program and its foundational retrospective, population-based cohort of Albertan residents diagnosed with a first primary neoplasm between the ages of 0 and 17 years from 1 January 2001 to 31 December 2018. The cohort was established in collaboration with the Alberta Cancer Registry and Cancer in Young People in Canada program and has been linked to existing administrative health databases and patient-reported outcome questionnaires. The cohort comprised 2580 survivors of childhood cancer, 1379 (53.4%) of whom were 5-year survivors. Approximately 48% of the cohort was female, 47% of the cohort was diagnosed between 0 and 4 years of age, and the most frequent diagnoses were leukemias (25.4%), central nervous system tumors (24.0%), and lymphomas (14.9%). Detailed treatment information was available for 1741 survivors (67.5%), with manual abstraction ongoing for those with missing data. By the study exit date, the median time since diagnosis was 5.5 years overall and 10.4 years for 5-year survivors. During the follow-up time, 82 subsequent primary cancers were diagnosed, 20,355 inpatient and 555,425 ambulatory/outpatient events occurred, 606,773 claims were reported, and 437 survivors died. The results from this research program seek to inform and improve clinical care and reduce cancer-related sequelae via tertiary prevention strategies.
Identifiants
pubmed: 37568747
pii: cancers15153932
doi: 10.3390/cancers15153932
pmc: PMC10417797
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Calgary
ID : CHW 2022
Organisme : Alberta Children's Hospital Foundation
ID : CHW 2022
Références
J Natl Cancer Inst. 2018 Jun 1;110(6):649-660
pubmed: 29165710
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 28419299
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1585-92
pubmed: 26189768
Br J Cancer. 2015 Sep 29;113(7):1121-32
pubmed: 26418531
Pediatr Blood Cancer. 2010 Aug;55(2):324-30
pubmed: 20582971
Thorax. 2018 Oct;73(10):959-968
pubmed: 29748251
Circulation. 2017 Mar 7;135(10):951-963
pubmed: 28082386
Int J Cancer. 2019 Apr 15;144(8):1796-1823
pubmed: 30098012
Dtsch Arztebl Int. 2017 Nov 24;114(47):805-812
pubmed: 29229046
JAMA. 2013 Jun 12;309(22):2371-2381
pubmed: 23757085
Eur J Cancer. 2019 Aug;117:71-83
pubmed: 31260818
Br J Cancer. 2015 Jun 9;112(12):1857-65
pubmed: 25989269
Med Pediatr Oncol. 2002 Apr;38(4):229-39
pubmed: 11920786
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Health Promot Chronic Dis Prev Can. 2015 Jun;35(4):73-6
pubmed: 26083522
BMJ. 2016 Sep 01;354:i4351
pubmed: 27586237
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
J Clin Oncol. 2016 May 20;34(15):1772-9
pubmed: 27022116
Cancer. 2018 Sep 1;124(17):3596-3608
pubmed: 30067866
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28954302
J Cancer Surviv. 2019 Aug;13(4):547-557
pubmed: 31250352
Pediatr Blood Cancer. 2008 May;50(5):1018-25
pubmed: 17849473
Cancer. 2014 Sep 1;120(17):2751-9
pubmed: 24824592
Acta Oncol. 2015 May;54(5):655-68
pubmed: 25813473
Med Care. 2010 Nov;48(11):1015-25
pubmed: 20940653
PLoS One. 2022 May 26;17(5):e0267317
pubmed: 35617253